Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 13/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201005 | 0.93 | HTR2C (0.34) | HTR2CSOS1KDM1A | |
| SCHEMBL4841841 | 0.91 | SOS1 (0.42) | HTR2CSOS1KDM1A | |
| SCHEMBL4842921 | 0.89 | HTR2C (0.38) | HTR2CSOS1KDM1A | |
| SCHEMBL5201999 | 0.81 | EPHX2 (0.44) | — | |
| SCHEMBL4841972 | 0.80 | SOS1 (0.44) | HTR2CSOS1KDM1AHTR3A | |
| SCHEMBL5185302 | 0.74 | TRPV1 (0.40) | — | |
| SCHEMBL4847436 | 0.70 | HTR2C (0.36) | HTR2CSOS1HTR3A | |
| SCHEMBL68342 | 0.70 | PIM1 (0.41) | HTR2CHTR3A | |
| SCHEMBL68028 | 0.68 | ACVR1 (0.42) | — | |
| SCHEMBL22828345 | 0.64 | DPP4 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | HTR2C 119/4885SOS1 2211/4885KDM1A 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.